Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.89 |
| ▸ | HSP90AB1 | P08238 | 17/20 | 0.89 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.76 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148457 | 1.00 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5148467 | 0.97 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5148470 | 0.97 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5147018 | 0.95 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5147021 | 0.95 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Snx 5422 SCHEMBL1220791 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Snx 5422 SCHEMBL1220790 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Snx 5422 SCHEMBL15604989 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL23133268 | 0.93 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12719897 | 0.93 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | claimed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | HRH4, P2RX4, CDK4 | HSP90AA1 3248/4885HSP90AB1 2805/4885HSP90B1 3218/4885 |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.